Biodexa Pharmaceuticals Plc (BDRX) Latest Company News

Oct 13, 2026, 12:30 UTC
Biodexa Pharmaceuticals announced that 100 patients had enrolled in its registrational Phase 3 Serenta trial of eRapa for familial adenomatous polyposis.
Source:
- globenewswire.com
Sep 23, 2026, 10:30 UTC
Biodexa Pharmaceuticals PLC CEO Stephen Stamp discussed the company's lead oral drug candidate eRapa for Familial Adenomatous Polyposis (FAP) in a fireside chat.
Source:
- accessnewswire.com
- hawaiitelegraph.com
Sep 15, 2026, 12:00 UTC
Biodexa Pharmaceuticals PLC entered into a warrant exercise agreement with an existing accredited investor for the exercise of 2,204,218 outstanding warrants at $1.05 per ADS, raising approximately $2.3 million in gross proceeds.
Source:
- globenewswire.com
Sep 11, 2026, 20:30 UTC
Biodexa Pharmaceuticals PLC announced its unaudited interim results for the six months ended June 30, 2026.
Source:
- globenewswire.com
Aug 19, 2026, 12:30 UTC
Biodexa Pharmaceuticals announced that its Serenta registrational Phase 3 trial for eRapa in Familial Adenomatous Polyposis has recruited 87 of 168 planned subjects, exceeding the halfway point.
Source:
- globenewswire.com
Jul 29, 2026, 20:30 UTC
Biodexa Pharmaceuticals PLC shareholders passed all four resolutions at the general meeting held on July 29, 2026.
Source:
- globenewswire.com
Jul 29, 2026, 12:30 UTC
Biodexa Pharmaceuticals held its first round table meeting in Paris, France to expand support activities for Familial Adenomatous Polyposis patients and treatment centers.
Source:
- globenewswire.com
Jun 30, 2026, 12:00 UTC
Biodexa Pharmaceuticals priced a $3.5 million combined registered direct offering, concurrent private placement, and warrant inducement, including 282,952 ADSs at $2.85 per ADS.
Source:
- globenewswire.com

BDRX

Biodexa Pharmaceuticals announced that 100 patients had enrolled in its registrational Phase 3 Serenta trial of eRapa for familial adenomatous polyposis.

Biodexa Pharmaceuticals PLC CEO Stephen Stamp discussed the company's lead oral drug candidate eRapa for Familial Adenomatous Polyposis (FAP) in a fireside chat.

Biodexa Pharmaceuticals PLC entered into a warrant exercise agreement with an existing accredited investor for the exercise of 2,204,218 outstanding warrants at $1.05 per ADS, raising approximately $2.3 million in gross proceeds.

Biodexa Pharmaceuticals PLC announced its unaudited interim results for the six months ended June 30, 2026.

Biodexa Pharmaceuticals announced that its Serenta registrational Phase 3 trial for eRapa in Familial Adenomatous Polyposis has recruited 87 of 168 planned subjects, exceeding the halfway point.

Biodexa Pharmaceuticals PLC shareholders passed all four resolutions at the general meeting held on July 29, 2026.

Biodexa Pharmaceuticals held its first round table meeting in Paris, France to expand support activities for Familial Adenomatous Polyposis patients and treatment centers.

Biodexa Pharmaceuticals priced a $3.5 million combined registered direct offering, concurrent private placement, and warrant inducement, including 282,952 ADSs at $2.85 per ADS.